Get the Stockscreener App
2.36
5.98%
-0.15
After Hours:
2.36
Aytu Biopharma Inc stock is traded at $2.36, with a volume of 185.78K.
It is down -5.98% in the last 24 hours and up +3.51% over the past month.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
See More
Previous Close:
$2.51
Open:
$2.55
24h Volume:
185.78K
Relative Volume:
0.93
Market Cap:
$21.19M
Revenue:
$93.76M
Net Income/Loss:
$-13.68M
P/E Ratio:
-0.8973
EPS:
-2.63
Net Cash Flow:
$8.77M
1W Performance:
+24.21%
1M Performance:
+3.51%
6M Performance:
+131.37%
1Y Performance:
+5.36%
1-Day Range:
$2.35
$2.59
1-Week Range:
$1.96
$2.59
52-Week Range:
$0.95
$2.82
Aytu Biopharma Inc Stock (AYTU) Company Profile
Name
Aytu Biopharma Inc
Sector
Phone
(720) 437-6580
Address
7900 E. UNION AVENUE, DENVER
Compare AYTU with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AYTU
Aytu Biopharma Inc
|
2.36 | 24.88M | 93.76M | -13.68M | 8.77M | -2.63 |
|
ZTS
Zoetis Inc
|
141.11 | 63.55B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.71 | 44.47B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.00 | 40.17B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.03 | 22.99B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
440.00 | 20.14B | 3.08B | 1.24B | 1.07B | 25.61 |
Aytu Biopharma Inc Stock (AYTU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-01-25 | Initiated | Lake Street | Buy |
| Jun-30-25 | Initiated | Ascendiant Capital Markets | Buy |
| Mar-30-21 | Initiated | Cantor Fitzgerald | Overweight |
| May-29-20 | Initiated | H.C. Wainwright | Buy |
Aytu Biopharma Inc Stock (AYTU) Latest News
What earnings revisions data tells us about Aytu BioPharma Inc.2025 Key Highlights & Precise Buy Zone Tips - newser.com
Using data models to predict Aytu BioPharma Inc. stock movementMarket Weekly Review & Low Volatility Stock Suggestions - newser.com
Aytu BioPharma to Present at Upcoming October 2025 Conferences - ACCESS Newswire
How to use Fibonacci retracement on Aytu BioPharma Inc.Analyst Upgrade & Community Supported Trade Ideas - newser.com
Why institutional investors increase stakes in Aytu BioPharma Inc. (AY20) stockAnalyst Upgrade & Verified Swing Trading Watchlists - newser.com
How institutional ownership impacts Aytu BioPharma Inc. stockWeekly Trade Analysis & Reliable Volume Spike Trade Alerts - newser.com
Aytu BioPharma Inc AY20 Stock Analysis and ForecastMomentum Trading Signals & Free Double Digit Growth Tips - earlytimes.in
What analysts say about Aytu BioPharma Inc stockTake Profit Strategies & Fast Profit Trading Tips - earlytimes.in
Is Aytu BioPharma Inc. (AY20) stock attractive for growth fundsJuly 2025 Levels & Risk Adjusted Swing Trade Ideas - newser.com
Can Aytu BioPharma Inc. (AY20) stock withstand sector downturnsEarnings Growth Report & Entry Point Strategy Guides - newser.com
Aytu BioPharma Reports Fiscal 2025 Earnings and EXXUA Launch Plans - MSN
Will Rising Interest Rates Hurt Lupin Limited’s Profit MarginsMarket Correction Analysis & Set Up Real-Time Alerts – It’s Free - earlytimes.in
Aytu BioPharma Inc. stock momentum explainedJuly 2025 Snapshot & High Accuracy Trade Alerts - newser.com
Applying sector rotation models to Aytu BioPharma Inc.Market Performance Report & Technical Pattern Recognition Alerts - newser.com
Aytu outlines EXXUA launch targeting $22B MDD market while streamlining ADHD portfolio - MSN
Is It Time to Lock in Profits on Mefcom Capital Markets Limited StockValue Stock Picks & Minimal Investment Capital Gains - earlytimes.in
What drives Aytu BioPharma Inc AY20 stock priceInterest Rate Changes & Minimal Risk High Reward - earlytimes.in
Aytu BioPharma at Lytham Partners: Strategic Realignment and Growth By Investing.com - Investing.com Canada
Aytu BioPharma (NASDAQ:AYTU) Downgraded by Wall Street Zen to “Hold” - Defense World
Aytu BioPharma (NASDAQ:AYTU) Given New $12.50 Price Target at Ascendiant Capital Markets - Defense World
Ascendiant Capital Maintains Aytu BioPharma (AYTU) Buy Recommendation - Nasdaq
Maxim Group Maintains Aytu BioPharma (AYTU) Buy Recommendation - Nasdaq
Aytu Biopharma Inc Stock (AYTU) Financials Data
Revenue
Net Income
Cash Flow
EPS
Aytu Biopharma Inc Stock (AYTU) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Disbrow Joshua R. | Chief Executive Officer |
Jun 09 '25 |
Buy |
1.50 |
66,666 |
99,999 |
153,257 |
| Disbrow Joshua R. | Chief Executive Officer |
Feb 28 '25 |
Buy |
1.30 |
15,000 |
19,500 |
86,591 |
1.54%
1.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):